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Summary 
Flavonols are polyphenolic compounds with reported cardiovascular benefits and antiplatelet 
properties. We have recently shown that the naturally occurring flavonol quercetin (Que) or 
the synthetic flavonol 3’,4’-dihydroxyflavonol (DiOHF) inhibit platelet function and delay 
thrombus formation in healthy mice. Diabetes is associated with increased cardiovascular 
risk, therefore, the aim of this study was to investigate the effect of daily 6 mg/kg 
intraperitoneal treatment of Que or DiOHF over 7 consecutive days on platelet aggregation, 
granule exocytosis and ferric chloride-induced carotid artery thrombosis in a mouse model of 
type 1 diabetes. Vehicle treated diabetic mice showed rapid thrombus formation, and 
achieved greater than 90% blood flow reduction within the 30 min of recording, while 
diabetic mice treated with 6 mg/kg of Que or DiOHF maintained blood flow at a significantly 
higher level at the end of the recording period. Platelets derived from diabetic mice were 
hyper-aggregable in response to platelet agonist stimulation when compared to the vehicle 
treated control mice, however, platelet aggregation in diabetic mice was significantly reduced 
with Que or DiOHF treatment. Treatment with 6 mg/kg of Que or DiOHF significantly 
inhibited dense granule exocytosis as measured by quinacrine uptake and release in diabetic 
and control mice, while there was no inhibitory effect on alpha granule exocytosis as 
measured by P-selectin expression in either diabetic or control mice. These data demonstrate 
that Que and DiOHF inhibit of platelet function and thrombus formation in vivo in a model of 
diabetes, and suggest a potential clinical role for flavonols as anti-platelet therapy. 
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Introduction 
Diabetes is a growing health problem and it has been estimated that the number of people 
with diabetes will rise to 439 million by 2030 worldwide [1]. In Australia approximately 
4.4% of the total population have been diagnosed with diabetes. In addition to its high 
prevalence, diabetes costs Australians in excess of $6 billion per year [2, 3]. Hyperglycaemia 
is often associated with macro-vascular complications [4], presenting as accelerated 
atherosclerosis leading to coronary, cerebral and peripheral arterial disease. Diabetes is 
therefore an important independent risk factor for cardiovascular disease (CVD) and a major 
contributor to cardiovascular events, particularly in Western countries. The incidence of CVD 
is between 2 and 4 times greater in people with diabetes [5], and people with diabetes have a 
poorer prognosis [6-8]. Indeed, recent reports from the World Health Organization (WHO) 
state that 50% of diabetic patients will die from CVD [9]. Thrombotic complications of 
cardiovascular disease, such as myocardial infarction (MI) and stroke, are responsible for up 
to 84% of deaths in people with diabetes aged 65 and older [5, 10]. In Australia it was 
reported that 65% of all CVD deaths occur in people with diabetes or impaired glucose 
metabolism [11]. Therefore it is vital develop new treatments to reduce diabetes-induced 
CVD. 
Antithrombotic agents are regularly used for both the primary and secondary prevention of 
cardiovascular events in diabetes [12, 13], but there is growing data to suggest inadequate 
cardiovascular protection by these agents [14]. A meta-analysis of randomized trials showed 
no significant benefit of aspirin in reducing clinical ischaemic events in people with diabetes 
[15-17], and therefore alternative therapies are required. Over the last decade many naturally 
occurring food components have been investigated for their health benefits, particularly, in 
reducing diabetes-induced complications [18]. Flavonols are one of the most common food 
derived polyphenolic compounds, which are associated with vascular beneficial properties 
[19]. 
The Rotterdam study showed a reduction in the occurrence of myocardial infarction with 
increased flavonol intake [20]. Furthermore, previous studies have shown that ingestion of 
flavonol rich foods and beverages reduce platelet aggregation [21-24]. Que is ubiquitously 
found in a variety of fruits and vegetables, and is one of the most abundant naturally 
occurring flavonols, [25]. We have recently shown that Que and DiOHF a synthetic flavonol 
of similar structure to Que, inhibit human platelet aggregation and dense granule exocytosis 
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in a concentration dependant manner [26]. Furthermore, we showed that the administration of 
Que or DiOHF at 6 mg/kg for seven consecutive days inhibits platelet function and reduces 
thrombus formation in a mouse model of platelet mediated arterial thrombosis [27].  
It has been reported in animal models of diabetes that treatment with Que restores endothelial 
function [28] and reduces pancreatic β-cell injury [29], systolic blood pressure, plasma lipids 
and plasma glucose levels [30, 31]. DiOHF also has demonstrated ability to prevent diabetes-
induced endothelial dysfunction [32], increase nitric oxide activity [33] and to restore 
endothelium dependent relaxation [34].Therefore, the aim of this study was to investigate the 
effects of Que or DiOHF on arterial thrombus formation and platelet function ex vivo in an 
animal model of diabetes. 
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Materials and Methods 
Animals   
All experimental procedures performed in this study were approved by the Animal 
Experimentation Ethics Committee of RMIT University and were conducted in accordance 
with the guidelines of the National Health and Medical Research Council of Australia for the 
care and use of animals for scientific purposes. 
Induction of diabetes and administration of investigational agents 
Diabetes was induced according to previously described methods [35, 36] with minor 
modifications. Briefly, diabetes was developed in C57BL/6 mice following a series of five 
intraperitoneal i.p. injections with streptozotocin (60 mg/kg) dissolved in citrate buffer. 
Diabetes was confirmed when the blood glucose level was > 13 mmol/L. Mice that did not 
develop diabetes within 4 days of the last STZ injection were given a second series of five 
STZ injections. Where blood glucose exceeded >30 mmol/L insulin was administered at 0.1 
to 0.2 U/mouse i.p. 2-3 times a week. Control mice received an equal amount of citrate buffer 
alone. Following 8 weeks of STZ-induced diabetes or an equivalent control period, mice 
were randomised to receive Que (6 mg/kg), DiOHF (6 mg/kg) or vehicle (0.5% DMSO plus 
20% polyethelene glycol (PEG) and saline), via i.p. injection daily for 7 days. Experimental 
procedures and blood collection were performed 24 h following the last treatment. 
Ferric chloride induced carotid injury  
Ferric chloride-induced arterial injury was performed as previously described [37]. Briefly, 
mice were anaesthetised with ketamine and xylazine (200: 10 mg/kg) by IP injection. A 
midline cervical incision was made and the carotid artery exposed. A laser Doppler flow 
probe (Moor Instruments, UK) was placed adjacent to the carotid artery to measure baseline 
blood flow. After baseline blood flow was established, a 2 x 4 mm filter paper saturated with 
20% ferric chloride was applied to the carotid artery on the adventitial surface of the carotid 
artery for 4 min. Following the removal of the filter paper blow flow through the carotid 
artery was monitored for 30 min, or until a 95% reduction in blood flow was reached. At the 
end of each experiment, and whilst the mouse was under deep anaesthesia, it was euthanized 
by cervical dislocation. 
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Sample preparation for platelet aggregation and dense granule exocytosis 
In separate mice, fresh whole blood was collected via cardiac puncture and placed into tubes 
containing 100 µl of 3.2% (w/v) sodium citrate. Platelet rich plasma (PRP) was obtained by 
centrifugation at 200 x g for 15 min at room temperature with no brake. Platelet poor plasma 
(PPP) was obtained by centrifugation of the remaining blood at 1200 x g for 15 min at room 
temperature. Platelet count was performed using a Beckman Coulter Ac.T 5 Haematology 
analyser (Coulter Corporation, USA). Platelet count was normalised in all treatment groups to 
100 x 10
9
 /L in Ringer citrate dextrose (RCD) buffer, pH 7.4 (108 mM NaCl, 38 mM KCl,1.7 
mM NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose, and 1.1 mM MgCl2 · 6 H2O, with 
pH adjusted to 7.4). 
Platelet aggregation  
Platelet aggregation was measured by turbidimetric aggregometry using a Chrono-log 700 
aggregometer (Chrono-log Corp, USA) [38]. In brief, PRP aggregation was performed in the 
presence of 100 µg / mL fibrinogen and 1 mM CaCl2 at 37°C with constant stirring (1000x 
rpm). Platelet aggregation baseline was set against murine PPP diluted 1: 2 in RCD buffer. 
Platelet aggregation was stimulated using 250 µM of the protease-activated receptor 4 (PAR 
4) agonist peptide H-Ala - Tyr - Pro - Gly - Lys - Phe -NH2 (AYPGKF-NH2) (GL chemicals, 
China). The maximal aggregation amplitude over a 9 minute period was recorded. 
Assessment of granule exocytosis 
Dense granule exocytosis was measured by flow cytometry using fluorescent quinacrine 
uptake and AYPGKF-NH2 induced release. Aliquots of mouse PRP were incubated with 100 
µM quinacrine at 37°C for 20 min in the dark. The platelets were then washed using RCD 
buffer by centrifugation at 500 x g for 10 min with no brake at room temperature and 
resuspended in RCD buffer. Aliquots were incubated with 250 µM AYPGKF-NH2 at 37°C 
for 5 min in the dark. The reaction was stopped by 1:12 dilution of RCD, and immediately 
analysed by flow cytometry. Alpha granule exocytosis was measured in separate aliquots of 
PRP by incubating with anti-mouse CD62P-PE (BD Pharmingen, USA) and 250 µM 
AYPGKF-NH2 at 37°C for 30 min. Flow cytometric analysis was performed using a 
FACSCanto II flow cytometer (BD Biosciences, USA) with excitation at 488 nm and 
quinacrine fluorescent emission collected in the range 515 – 545 nm and CD62P-PE 
fluorescent emission collected in the range 564 – 606 nm. Staining in separate aliquots 
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prevented the need for compensation of spectral overlap. 10,000 individual platelets were 
analysed. Dense granule exocytosis was recorded as the percentage of decrease in 515 – 545 
nm fluorescence intensity when compared to unstimulated platelets, while alpha granule 
exocytosis was recorded as CD62P mean fluorescent intensity (MFI). 
 
Statistical analysis 
All values are expressed as mean ± standard error of the mean (SEM). Comparisons between 
test samples and control were performed using one-way ANOVA test with Dunnett’s test, for 
post hoc comparisons. An unpaired Student’s t-test was performed to compare diabetic and 
non-diabetic platelet aggregation and dense granule exocytosis. 
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Results 
Weight and plasma glucose levels 
Over the 8 week period, the STZ-treated mice gained less weight compared to non-diabetic 
control (Figure 1A). Similarly, the blood glucose levels in STZ-treated mice were 
significantly higher than non-diabetic mice (Figure 1B). 
Effect of Que and DiOHF on FeCl3 induced arterial thrombosis 
Diabetic mice showed rapid thrombus formation when compared to the non-diabetic mice. In 
vehicle treated diabetic mice, carotid blood flow was reduced to 50±17% of baseline 5 min 
after application of FeCl3 (Fig 2A), while vehicle treated control mice maintained greater 
than 90% blood flow at the same time (94±7% flow, p < 0.05 vs. diabetic vehicle treated 
mice, Fig 2B). However, at 15 min after application of FeCl3 both diabetic and non-diabetic 
vehicle treated mice had near complete vessel occlusion (1±1% flow vs 6±1% flow, 
respectively, p < 0.05. between diabetic and non-diabetic mice, Figs 2 A&B). There was no 
blood flow at 30 min as there was total occlusion in vehicle treated diabetic and non-diabetic 
mice. 
Treatment of diabetic mice with 6 mg/kg of Que or DiOHF significantly improved blood 
flow in the carotid artery at 5 min (Que 94 ± 5% flow, DiOHF 93±7% flow, p < 0.05 vs. 
diabetic vehicle treated mice, Fig 2A). At 15 min flavonol treated diabetic mice maintained 
significant blood flow (Que 61±15% flow, DiOHF 83±18% flow, p < 0.05 vs. diabetic 
vehicle treated mice, Fig 2A). Similarly, blood flow at 15 min was well maintained in non-
diabetic mice treated with 6 mg/kg of either Que or DiOHF (Que 91±6% flow, DiOHF 
70±18% flow, p < 0.05 vs. non-diabetic vehicle treated mice, Fig 2B). Blood flow at 30 min 
after FeCl3 injury was well maintained in diabetic mice treated with the flavonols (Que 
48±21% flow, DiOHF 52±19% flow, Fig 2A).  
In contrast, when non-diabetic mice were treated with the flavonols, both Que and DiOHF 
maintained blood flow 30 min after FeCl3 injury, however Que maintained higher blood flow 
when compared to DiOHF (Que 75±18% flow, DiOHF 53±26% flow, Fig 2B). When blood 
flow in both diabetic and non-diabetic mice was expressed as the area under the curve 
flavonol treated mice showed significantly greater blood flow than vehicle treated diabetic 
and non-diabetic mice, see Fig 3. 
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Effect of Que and DiOHF on platelet aggregation 
Platelets derived from diabetic mice showed a higher level of aggregation to AYPGKF-NH2 
stimulation when compared to the vehicle treated control mice (102±9% diabetic platelets vs. 
78±2% control platelets, p <0.05). Platelet hyper-aggregability in diabetic mice was 
significantly reduced following 7 day treatment with Que or DiOHF (64±7and 70±9%, 
respectively, p < 0.05 vs. vehicle, Fig 4A). In control mice Que or DiOHF treatments, as 
expected, significantly reduced platelet aggregation (Que 53±6% and DiOHF 53±10%, p < 
0.05 vs. vehicle, Fig 4B).  
Effect of Que and DiOHF on granule exocytosis 
There was no significant difference in dense granule exocytosis, as measured by quinacrine 
release, between vehicle treated diabetic and non-diabetic mice in response to AYPGKF-NH2 
stimulation (51±4% vs. 58±3%, p >0.05). Treatment with 6 mg/kg of Que or DiOHF 
significantly inhibited dense granule exocytosis in diabetic (Que 34±4% and DiOHF 34±3%, 
p < 0.05 vs. vehicle, Fig 5A1), and non-diabetic mice (Que 48± 3% and DiOHF 46±2%, p 
<0.05 vs. vehicle, Fig 5A2).  
Treatment with 6 mg/kg of Que or DiOHF did not produce an inhibitory effect on alpha 
granule exocytosis as measured by P-selectin expression induced by AYPGKF-NH2 in either 
diabetic (Que 2850±334 fluorescence intensity and DiOHF 3328±420 fluorescence intensity 
vs. vehicle 3296±619 fluorescence intensity, p >0.05, Fig 5B1) or non-diabetic mice (Que 
2671±463 fluorescence intensity and DiOHF 3306±694 fluorescence intensity vs. vehicle 
3257±297 fluorescence intensity, p >0.05, Fig 5B2). 
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Discussion 
In this study we have shown that i.p. treatment with Que or DiOHF for seven consecutive 
days delay thrombus formation in a model of platelet mediated thrombosis in type 1 diabetic 
mice. Furthermore, we show the delay in thrombus formation is at least in part due to the 
inhibition of platelet aggregation and dense granule exocytosis.  
Platelet hyper-sensitivity plays a major role in cardiovascular complications of diabetes [39, 
40], therefore the aim of the study was to investigate the effects of Que and DiOHF on 
platelet function and thrombus formation. In this study STZ was used to induce type 1 
diabetes in C57BL/6 mice. FeCl3 was used to induce arterial thrombosis in the carotid artery. 
FeCl3 induces platelet mediated thrombus formation by damaging the endothelial lining, 
causing RBC haemolysis and haemoglobin oxidation. This leads to ROS production, causing 
further endothelial damage, resulting in increased platelet activation and adhesion at the site 
of injury [41]. 
Diabetic mice showed rapid thrombus formation when compared to healthy mice. Indeed, 
thrombus formation in diabetic mice commenced prior to the removal of the FeCl3 strip, and 
when the FeCl3 strip was removed blood flow had fallen below the base line. In contrast, non-
diabetic mice maintained 100% blood flow during and after FeCl3 application. Furthermore, 
at 5 min after FeCl3 application blood flow in diabetic mice was less than 50% of baseline, 
whilst blood flow in control mice was close to pre-injury levels. This supports previous 
observations that in mice, hyperglycaemia accelerates thrombus formation when induced by 
FeCl3 [42], and suggests that diabetes accelerates thrombus formation, but there is no 
difference in the magnitude of thrombus formation over 30 min. The accelerated thrombus 
generation following arterial injury in diabetic mice observed in this study corresponded to 
enhanced agonist stimulated platelet aggregation. It is well established that impairment of 
endothelial function is associated with diabetes, and is likely to contribute to the accelerated 
thrombus generation in diabetics. This may be due to the reduced production of NO [43] and 
other vasorelaxant and antithrombotic agents such as prostacyclin from the endothelial cells 
[44], in addition to the enhanced platelet aggregation associated with this disease state.   
Treatment with 6 mg/kg of either Que or DiOHF significantly improved blood flow and 
delayed thrombus formation in diabetic mice. Indeed, blood flow in flavonol treated diabetic 
mice was maintained to near 100% flow 5 min after FeCl3 application, and there was no 
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significant difference in blood flow between diabetic and non-diabetic mice at that time of 
recording. In addition, full vessel occlusion did not occur at 30 min after FeCl3 injury.  
 In our diabetic model, platelets were found to be hyper-aggregable in response to AYPGKF-
NH2 when compared to non-diabetic mice, which is in agreement with previous observations 
that diabetic animals show enhanced platelet aggregation [45-47], and also corresponds with 
the rapid formation of a platelet mediated thrombus. On the other hand, alpha and dense 
granule exocytosis was not significantly different between diabetic and non-diabetic mice. 
Treatment with 6 mg/kg of Que or DiOHF for seven consecutive days significantly reduced 
platelet aggregation, and inhibited dense, but not alpha, granule exocytosis in response to 
AYPGKF-NH2. Platelet aggregation was reduced by more than 30% in platelets from 
diabetic mice and the levels were similar to that of the non-diabetic mice.  
Although the delay in thrombus formation observed in this study corresponds to the reduction 
of platelet aggregation and dense granule exocytosis, it is likely that the effect of these 
flavonols on endothelial function also contributed to the overall vascular benefits achieved. 
Que and DiOHF have been reported to produce potent vasoprotective effects on both healthy 
and diabetic models. Que has also been demonstrated to exert beneficial vascular effects in a 
range of pathological conditions including diabetes [48-50]. Indeed, it has been shown to 
restore endothelial relaxation in diabetes in response to acetylcholine, increase NO, neutralise 
free radicals and reduce oxidative damage in STZ treated rats [28, 51, 52]. Que has also been 
reported to inhibit lipid peroxidation via inhibition of xanthine oxidase [53].  
This study demonstrates that 6 mg/kg of the flavonols is capable of delaying thrombus 
formation in diabetes, which is consistent with our previous studies [32-34] reporting daily 
i.p. treatments of 5 mg/kg of flavonols for 7 days, reduced O2ˉ formation and prevented 
endothelial dysfunction in diabetes. Freedman et al [23] showed reduced platelet aggregation 
and enhanced NO production following the consumption of 7 mL/kg per day of purple grape 
juice for 14 days. 
This study provides evidence that naturally occurring and synthetic flavonols are able to 
produce beneficial effects in the vasculature in the context of a diabetic hyper-thrombotic 
state. Therefore, further investigation of supplementation and optimal doses that are capable 
of producing beneficial effects in humans are warranted,  
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An unexpected finding of this study was an absence of any inhibition of alpha granule 
exocytosis by the flavonols, whereas inhibition of dense granule exocytosis was observed. 
Platelet alpha granule secretion occurs more readily than dense granule secretion, however 
the mechanisms leading to membrane fusion and exocytosis of the two granule types have 
generally been assumed to be similar [54, 55]. By contrast studies have shown that aspirin is 
capable of inhibiting ADP-induced serotonin release (a dense granule component) whilst P-
selectin expression is unaffected [55], suggesting potential for selective inhibition of 
exocytosis by the different granule types. The results obtained in the current study suggest a 
similar mechanism of selective inhibition of dense granule exocytosis whilst alpha granule 
exocytosis is maintained. Further investigation, including investigation of different 
concentrations of the flavonols, and exocytosis induced by different chemical agonists, is 
warranted before conclusions can be drawn from this interesting observation. Given the 
ability of these flavonols to restore blood flow and platelet aggregation in diabetic mice to 
normal levels, more studies are warranted to determine optimal doses, and also structural 
modifications to these compounds that might increase the antithrombotic potency. 
 Limitations 
This study demonstrates improved blood flow and reduced platelet hyper-sensitivity in type 1 
diabetes, and although the pathology in type 1 and 2 diabetes is similar, these improvements 
also need to be demonstrated in type 2 diabetes. Furthermore, reduced platelet aggregation 
might be associated with increased bleeding risks, and although significant bleeding was not 
observed, appropriate studies investigating the effect of these flavonols on bleeding times are 
warranted. 
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Figure 1.  STZ-induced diabetes in C57BL/6 mice. A) Weight of diabetic and non-diabetic mice over 
the 8 week period, and B) Plasma glucose levels of diabetic and non-diabetic mice during the 8 week 
period, n= 35 each group. 
Figure 2.   Mean arterial blood flow expressed as a percentage of baseline. A) Carotid blood flow in 
diabetic mice treated with 6 mg/kg Que, 6 mg/kg DiOHF or vehicle control following ferric chloride 
induced arterial injury. (B) Carotid blood flow in non-diabetic mice treated with 6 mg/kg Que, 6 
mg/kg DiOHF or vehicle control following ferric chloride induced arterial injury, n= 4 for each 
treatment group. For clarity, flow is shown as the mean without sem. 
Figure 3.  Carotid artery blood flow expressed as the area under the curve (AUC) over 30 min for the 
mice treated with 6 mg/kg Que, 6 mg/kg DiOHF or vehicle control following ferric chloride induced 
arterial injury. (A) Diabetic mice. (B) Non-diabetic mice. * P < 0.05 vs vehicle. Mean  SEM. One 
way ANOVA with Dunnett’s post test. 
Figure 4.  Platelet aggregation stimulated with AYPGKF-NH2 (250 µM). Platelets were obtained 
from diabetic and non-diabetic mice treated with 6 mg/kg Que (n = 5), DiOHF (n = 5) or vehicle (n = 
4). Platelet count was normalised to 100x10
9
/L in all test groups. (A) Diabetic mice. (B) Non-diabetic 
mice. * P < 0.05 vs vehicle. Mean  SEM. One way ANOVA with Dunnett’s post test. 
Figure 5.   Granule exocytosis stimulated with PAR 4 agonist peptide (250 µM). Platelets were 
obtained from diabetic and non-diabetic mice treated with 6 mg/kg Que (n=6), DiOHF (n=6) or 
vehicle (n=6). Platelet count was normalised to 100x10
9
/L in all test groups. (A1) Dense granule 
exocytosis as measured by quinacrin uptake and release in diabetic mice. (A2) Dense granule 
exocytosis as measured by quinacrin uptake and release in non-diabetic mice. (B1) Alpha granule 
exocytosis as measured by the mean fluorescence intensity of P-Selectin expression in diabetic mice. 
(B1) Alpha granule exocytosis as measured by the mean fluorescence intensity of P-Selectin 
expression in non-diabetic mice.  * P < 0.05 vs vehicle. Mean  SEM. One way ANOVA with 
Dunnett’s post test. 
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